Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235856 | 0.85 | — | — | |
| SCHEMBL154974 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL1673059 | 0.85 | ALOX15 (0.44) | ALDH1A1KDM4EPKMHRH3POLB | |
| SCHEMBL10829091 | 0.85 | ALOX15 (0.44) | ALDH1A1KDM4EPKMHRH3POLB | |
| SCHEMBL3971866 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL8775141 | 0.85 | — | — | |
| SCHEMBL13833159 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL11139073 | 0.82 | ALDH1A1 (0.62) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| Fluoride SCHEMBL11242906 | 0.82 | ALDH1A1 (0.70) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| Hydrochloric Acid SCHEMBL15993888 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270707-A1 | \"Good\" buffer-based cationic lipids | TRANSLATE BIO, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4323346-A1 | GOOD\"BUFFER-BASED CATIONIC LIPIDS | Translate Bio, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-117136182-A | Cationic lipids based on \"God\" buffers | 翻译生物公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023198857-A1 | \"GOOD\" BUFFER-BASED CATIONIC LIPIDS | SANOFI (FR) | 2023-10-19 | — | — | WO | disclosed |
| US-11771653-B2 | Lipid nanoparticles for delivering mRNA vaccines | SANOFI (FR) | 2023-10-03 | — | — | US | disclosed |
| US-11771652-B2 | Lipid nanoparticles for delivering mRNA vaccines | SANOFI (FR) | 2023-10-03 | — | — | US | disclosed |
| US-11771652-B2 | Lipid nanoparticles for delivering mRNA vaccines | SANOFI (FR) | 2023-10-03 | — | — | US | disclosed |
| US-11771653-B2 | Lipid nanoparticles for delivering mRNA vaccines | SANOFI (FR) | 2023-10-03 | — | — | US | disclosed |
| US-20230043128-A1 | MULTIVALENT INFLUENZA VACCINES | SANOFI PASTEUR INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2022221688-A1 | \"GOOD\"BUFFER-BASED CATIONIC LIPIDS | TRANSLATE BIO, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-2970180-A1 | PYRROLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS | Lupin Limited (IN) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014141091-A1 | PYRROLE DERIVATIVES AS ALPHA 7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2007071377-A1 | CONVERSION REAGENT AND METHOD AND KIT FOR DETERMINING HAEMOGLOBIN | MEDISYNTHANA DIAGNOSTICS GMBH & CO. KG (DE) | 2007-06-28 | — | — | WO | disclosed |
| EP-0032456-B1 | METHOD FOR HIGH CONTRAST DEVELOPMENT OF PHOTOGRAPHIC ELEMENTS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1983-02-02 | — | — | EP | disclosed |
| EP-0032456-A1 | Method for high contrast development of photographic elements | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1981-07-22 | — | — | EP | disclosed |
| US-4278674-A | ANTIBACTERIAL ANTIBIOTICS | SANDOZ LTD. (CH) | 1981-07-14 | — | — | US | disclosed |
| US-4269929-A | USING AN AQUEOUS ALKALINE SOLUTION CONTAINING DIHYDROXYBENZENE AND 3-PYRAZOLIDONE DEVELOPERS, A SULFITE PRESERVATIVE AND A CONTRAST-PROMOTING AMINE IN THE PRESENCE OF A HYDRAZIDE; LITHOGRAPHY | EASTMAN KODAK COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
| US-4208326-A | ANTIBIOTICS | SANDOZ LTD. (CH) | 1980-06-17 | — | — | US | disclosed |
| US-4107164-A | ANTIBIOTICS, ANTIBACTERIAL | SANDOZ LTD. (CH) | 1978-08-15 | — | — | US | disclosed |
| US-4032530-A | ANTIBIOTICS | SANDOZ LTD. (CH) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771653-B2 | Lipid nanoparticles for delivering mRNA vaccines | RNMT, NSUN3, RNGTT | ALDH1A1 3610/4885KDM4E 4001/4885KMT2A 1873/4885 |
| US-11771652-B2 | Lipid nanoparticles for delivering mRNA vaccines | RNMT, NSUN3, RNGTT | ALDH1A1 3610/4885KDM4E 4001/4885KMT2A 1873/4885 |
| US-20240270707-A1 | \"Good\" buffer-based cationic lipids | SLC7A1, LIPA, ASAH2 | ALDH1A1 1619/4885KDM4E 3710/4885KMT2A 2254/4885 |
| US-20230043128-A1 | MULTIVALENT INFLUENZA VACCINES | RNMT, RNGTT, OSBPL3 | ALDH1A1 4717/4885KDM4E 2002/4885KMT2A 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.